ACR-话题@MedSci

#ACR#

285篇内容 | 2287人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1400489, encodeId=dda61400489b8, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用, objectType=article, longId=196499, objectId=fcb619649997, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcb619649997, replyNumber=0, likeNumber=70, createdTime=2020-06-27, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcb619649997, moduleTitle=AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcb619649997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400488, encodeId=e6d01400488c2, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗, objectType=article, longId=196482, objectId=3e9419648230, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e9419648230, replyNumber=0, likeNumber=48, createdTime=2020-06-27, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e9419648230, moduleTitle=AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e9419648230)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400487, encodeId=828f140048e6a, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：NK细胞疗法ACE1702展示了积极的临床前数据, objectType=article, longId=196313, objectId=dbde196313ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbde196313ba, replyNumber=0, likeNumber=60, createdTime=2020-06-25, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbde196313ba, moduleTitle=AACR 2020：NK细胞疗法ACE1702展示了积极的临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbde196313ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400486, encodeId=4051140048617, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=2020 AACR：多功能溶瘤病毒BT-001对实体瘤具有强大活性, objectType=article, longId=194260, objectId=89fa194260ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89fa194260ac, replyNumber=0, likeNumber=0, createdTime=2020-05-18, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89fa194260ac, moduleTitle=2020 AACR：多功能溶瘤病毒BT-001对实体瘤具有强大活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89fa194260ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400485, encodeId=6a631400485e3, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果, objectType=article, longId=193387, objectId=c66b19338e62, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c66b19338e62, replyNumber=0, likeNumber=92, createdTime=2020-05-04, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c66b19338e62, moduleTitle=AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c66b19338e62)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400484, encodeId=491014004844b, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, objectType=article, longId=193348, objectId=1c5c193348ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c5c193348ad, replyNumber=0, likeNumber=63, createdTime=2020-05-03, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c5c193348ad, moduleTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c5c193348ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400483, encodeId=a034140048374, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：靶向联合免疫治疗显著延长BRAF突变晚期黑色素瘤患者无进展生存（IMspire150试验）, objectType=article, longId=193346, objectId=688d193346bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=688d193346bb, replyNumber=0, likeNumber=67, createdTime=2020-05-03, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=688d193346bb, moduleTitle=AACR 2020：靶向联合免疫治疗显著延长BRAF突变晚期黑色素瘤患者无进展生存（IMspire150试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=688d193346bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400482, encodeId=b3df1400482a0, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, objectType=article, longId=193345, objectId=a58619334571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a58619334571, replyNumber=0, likeNumber=64, createdTime=2020-05-03, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a58619334571, moduleTitle=AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a58619334571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400481, encodeId=cb24140048128, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：索凡替尼联合特瑞普利单抗治疗晚期实体瘤Ⅰ期研究结果公布, objectType=article, longId=193342, objectId=4e5d193342f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5d193342f4, replyNumber=0, likeNumber=73, createdTime=2020-05-03, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5d193342f4, moduleTitle=AACR 2020：索凡替尼联合特瑞普利单抗治疗晚期实体瘤Ⅰ期研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e5d193342f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400480, encodeId=17a71400480dc, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：CAR-T治疗复发性或难治性(R/R)急性T淋巴细胞白血病试验初步结果公布, objectType=article, longId=193184, objectId=fb6d193184c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb6d193184c5, replyNumber=0, likeNumber=91, createdTime=2020-05-01, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb6d193184c5, moduleTitle=AACR 2020：CAR-T治疗复发性或难治性(R/R)急性T淋巴细胞白血病试验初步结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb6d193184c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400479, encodeId=5c2614004e98a, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：MET新药Bozitinib用于NSCLC，疾病控制率90%, objectType=article, longId=193183, objectId=1bf61931836e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bf61931836e, replyNumber=0, likeNumber=58, createdTime=2020-05-01, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bf61931836e, moduleTitle=AACR 2020：MET新药Bozitinib用于NSCLC，疾病控制率90%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bf61931836e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400478, encodeId=9ed514004e867, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：KRAS新药用于NSCLC结果公布, objectType=article, longId=193182, objectId=863c19318287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=863c19318287, replyNumber=0, likeNumber=51, createdTime=2020-05-01, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=863c19318287, moduleTitle=AACR 2020：KRAS新药用于NSCLC结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=863c19318287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400477, encodeId=345c14004e7c3, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%, objectType=article, longId=193181, objectId=fa86193181f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa86193181f6, replyNumber=0, likeNumber=68, createdTime=2020-05-01, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa86193181f6, moduleTitle=AACR 2020：EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa86193181f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400476, encodeId=acbd14004e64d, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：蔡红兵教授分享COVID-19疫情癌症患者的数据, objectType=article, longId=193180, objectId=31a5193180d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31a5193180d8, replyNumber=0, likeNumber=62, createdTime=2020-05-01, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31a5193180d8, moduleTitle=AACR 2020：蔡红兵教授分享COVID-19疫情癌症患者的数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31a5193180d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400475, encodeId=c2d514004e5cd, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：肝内胆管癌的FGFR2一个新型突变被发现, objectType=article, longId=193179, objectId=833e1931e9c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=833e1931e9c2, replyNumber=0, likeNumber=79, createdTime=2020-05-01, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=833e1931e9c2, moduleTitle=AACR 2020：肝内胆管癌的FGFR2一个新型突变被发现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=833e1931e9c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400474, encodeId=352714004e4cd, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：PD-L1+恩杂鲁胺治疗去势抵抗性前列腺癌，未获成功, objectType=article, longId=193178, objectId=3bf01931e84c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bf01931e84c, replyNumber=0, likeNumber=77, createdTime=2020-05-01, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bf01931e84c, moduleTitle=AACR 2020：PD-L1+恩杂鲁胺治疗去势抵抗性前列腺癌，未获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bf01931e84c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400473, encodeId=d93614004e395, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：基因治疗肾细胞癌获突破，DCR可达75%！, objectType=article, longId=193177, objectId=1d271931e730, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d271931e730, replyNumber=0, likeNumber=108, createdTime=2020-05-01, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d271931e730, moduleTitle=AACR 2020：基因治疗肾细胞癌获突破，DCR可达75%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d271931e730)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400472, encodeId=120214004e2e8, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：KRAS突变在不同癌肿的发生率, objectType=article, longId=193176, objectId=cdb61931e68c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdb61931e68c, replyNumber=0, likeNumber=61, createdTime=2020-05-01, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdb61931e68c, moduleTitle=AACR 2020：KRAS突变在不同癌肿的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdb61931e68c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400471, encodeId=63da14004e124, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：免疫联合治疗在三阴性乳腺癌治疗中获突破，OS高达16个月, objectType=article, longId=193174, objectId=9c411931e4ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c411931e4ea, replyNumber=0, likeNumber=82, createdTime=2020-05-01, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c411931e4ea, moduleTitle=AACR 2020：免疫联合治疗在三阴性乳腺癌治疗中获突破，OS高达16个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c411931e4ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1400470, encodeId=20cd14004e078, content=<a href='/topic/show?id=e7c018e7af' target=_blank style='color:#2F92EE;'>#ACR#</a>, objectTitle=AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高, objectType=article, longId=193172, objectId=24cd1931e229, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24cd1931e229, replyNumber=0, likeNumber=62, createdTime=2020-05-01, rootId=0, userName=10518094zz, userId=19792261142, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24cd1931e229, moduleTitle=AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24cd1931e229)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ACR

2020-05-29

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：IL-15超激动剂SO-C101展现出强大的抗肿瘤作用

2020-06-27

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：口服PD-L1抑制剂CCX559，小鼠体内抗肿瘤效果优于PD-1/PD-L1单抗

2020-06-27

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：NK细胞疗法ACE1702展示了积极的临床前数据

2020-06-25

10518094zz (审核中...)

前往app查看评论内容

#ACR#

2020 AACR：多功能溶瘤病毒BT-001对实体瘤具有强大活性

2020-05-18

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：季加孚教授汇报PD-1/CTLA-4双抗AK104联合化疗一线治疗晚期胃或胃食管结合部癌的Ib期研究结果

2020-05-04

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）

2020-05-03

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：靶向联合免疫治疗显著延长BRAF突变晚期黑色素瘤患者无进展生存（IMspire150试验）

2020-05-03

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS（FLAURA研究）

2020-05-03

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：索凡替尼联合特瑞普利单抗治疗晚期实体瘤Ⅰ期研究结果公布

2020-05-03

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：CAR-T治疗复发性或难治性(R/R)急性T淋巴细胞白血病试验初步结果公布

2020-05-01

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：MET新药Bozitinib用于NSCLC，疾病控制率90%

2020-05-01

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：KRAS新药用于NSCLC结果公布

2020-05-01

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%

2020-05-01

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：蔡红兵教授分享COVID-19疫情癌症患者的数据

2020-05-01

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：肝内胆管癌的FGFR2一个新型突变被发现

2020-05-01

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：PD-L1+恩杂鲁胺治疗去势抵抗性前列腺癌，未获成功

2020-05-01

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：基因治疗肾细胞癌获突破，DCR可达75%！

2020-05-01

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：KRAS突变在不同癌肿的发生率

2020-05-01

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：免疫联合治疗在三阴性乳腺癌治疗中获突破，OS高达16个月

2020-05-01

10518094zz (审核中...)

前往app查看评论内容

#ACR#

AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高

2020-05-01

科室
- - 订阅+
  - 更多科室
工具
服务